| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-10-28 | ASP2215 - gilteritinib | acute myeloid leukemia | 3 | Astellas Pharma (Japan) | Cancer - Oncology |
| 2015-10-28 | obeticholic acid (OCA) | NASH (non-alcoholic steatohepatitis) | 2 | Intercept Pharmaceuticals (USA - NY) Sumitomo Dainippon Pharma (Japan) | Liver diseases - Hepatic diseases |
| 2015-10-27 | lifitegrast | dry eye disease | 3 | Shire (UK - USA) | Ophtalmological diseases |
| 2015-10-27 | Onivyde™ (MM-398 - nanoliposomal irinotecan injection) | previously untreated, metastatic pancreatic adenocarcinoma | 2 | Baxalta (USA - IL) Merrimack Pharmaceuticals (USA - MA) | Cancer - Oncology |
| 2015-10-27 | CureXcell® | diabetic foot ulcers | 3 | Macrocure (Israel) | Metabolic diseases - Cardiovascular diseases - Regenerative Medicine |
| 2015-10-26 | ABP-700 | general anesthesia, procedural sedation | 1 | The Medicines Company (USA - NJ) | CNS diseases |
| 2015-10-26 | ASP8273 - naquotinib mesylate | non-small cell lung cancer (NSCLC) | 3 | Astellas Pharma (Japan) | Cancer - Oncology |
| 2015-10-25 | azacitidine | nasopharyngeal neoplasms | 2 | Celgene (USA - NJ) | Cancer - Oncology - Rare diseases |
| 2015-10-25 | Sativex® (Delta-9-Tetrahydro-cannabinol (THC) and Cannabidiol (CBD) | pain in patients with advanced cancer | 3 | GW Pharmaceuticals (UK) Otsuka Pharmaceuticals (Japan) | Cancer - Oncology - CNS diseases |
| 2015-10-23 | APR-246 in combination with carboplatin and pegylated doxorubicin | ovarian cancer | 1-2 | Aprea (Sweden) | Cancer - Oncology - Rare diseases |
| 2015-10-23 | house dust mite sublingual immunotherapy tablet (STG320) | allergic asthma | 2 | Ares Allergy (UK) | Allergic diseases - Inflammatory diseases - Respiratory diseases |
| 2015-10-22 | roxadustat | anemia associated with chronic kidney disease (CKD) | 2 | FibroGen (USA - CA) | Kidney diseases - Renal diseases |
| 2015-10-22 | margetuximab and pembrolizumab | advanced HER2-positive gastric cancer | 1b-2 | Macrogenics (USA - MD) Merck&Co (USA - NJ) | Cancer - Oncology |
| 2015-10-21 | avelumab in combination with crizotinib or lorlatinib (PF-06463922) | non-small cell lung cancer (NSCLC) | 2 | Pfizer (USA - NY) | Cancer - Oncology |
| 2015-10-20 | SENS-200 | hearing loss resulting from acoustic trauma | preclinical | Sensorion (France) | Otorhinolaryngology |
| 2015-10-20 | RXI-109 | hypertrophic scar | 2 | RXi Pharmaceuticals (USA - MA) | Dermatological diseases |
| 2015-10-19 | selinexor (KPT-330 - (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide) | multiple myeloma | 1-2 | Karyopharm Therapeutics (USA - MA) | Cancer - Oncology |
| 2015-10-16 | AG-221 (enasidenib) | acute myeloid leukemia (AML) | 3 | Celgene (USA - NJ) Agios Pharmaceuticals (USA -MA) | Cancer - Oncology |
| 2015-10-16 | lenvatinib in combination with everolimus | metastatic renal cell carcinoma (mRCC) following prior VEGF-targeted therapy | 2 | Eisai (Japan) | Cancer - Oncology |
| 2015-10-16 |
